MDxHealth provides actionable molecular diagnostic information to personalise the diagnosis and treatment of cancer. Our tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies to assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy.


We believe that our proprietary, accurate and scalable epigenetic technologies provide a key competitive advantage in the diagnosis, prognosis and management of cancer. In addition to our ongoing and planned studies for our tests to assess the risk of prostate cancer (ConfirmMDx and SelectMDx) and bladder cancer (AssureMDx), our product pipeline includes tests for kidney and other urologic cancers.

Version: 14/9/2017